Rani Therapeutics Holdings (RANI) Non-Current Deffered Revenue (2025)
Rani Therapeutics Holdings (RANI) posted quarterly Non-Current Deffered Revenue of $1.7 million for Q4 2025.
Rani Therapeutics Holdings (RANI) Non-Current Deffered Revenue (2025) Analysis & Trends
Rani Therapeutics Holdings' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $1.7 million for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (changed N/A YoY), while the FY2025 annual figure was $1.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $1.7 million.
- The five-year high for Non-Current Deffered Revenue was $1.7 million in Q4 2025, with the low at $1.7 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.71 Mn |